| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1953 | 2020 |
| Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer L Derosa, B Routy, AM Thomas, V Iebba, G Zalcman, S Friard, J Mazieres, ... Nature medicine 28 (2), 315-324, 2022 | 407 | 2022 |
| Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ... Annals of oncology 32 (6), 787-800, 2021 | 323 | 2021 |
| Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade MC Andrews, CPM Duong, V Gopalakrishnan, V Iebba, WS Chen, ... Nature medicine 27 (8), 1432-1441, 2021 | 316 | 2021 |
| Moving towards personalized treatments of immune-related adverse events K Esfahani, A Elkrief, C Calabrese, R Lapointe, M Hudson, B Routy, ... Nature reviews Clinical oncology 17 (8), 504-515, 2020 | 265 | 2020 |
| The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non–small cell lung cancer T Hakozaki, C Richard, A Elkrief, Y Hosomi, M Benlaïfaoui, I Mimpen, ... Cancer Immunology Research 8 (10), 1243-1250, 2020 | 239 | 2020 |
| The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? A Elkrief, L Derosa, G Kroemer, L Zitvogel, B Routy Annals of Oncology 30 (10), 1572-1579, 2019 | 209 | 2019 |
| Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial B Routy, JG Lenehan, WH Miller Jr, R Jamal, M Messaoudene, ... Nature medicine 29 (8), 2121-2132, 2023 | 190 | 2023 |
| Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors A Elkrief, L El Raichani, C Richard, M Messaoudene, W Belkaid, J Malo, ... Oncoimmunology 8 (4), e1568812, 2019 | 186 | 2019 |
| A natural polyphenol exerts antitumor activity and circumvents anti–PD-1 resistance through effects on the gut microbiota M Messaoudene, R Pidgeon, C Richard, M Ponce, K Diop, M Benlaifaoui, ... Cancer Discovery 12 (4), 1070-1087, 2022 | 153 | 2022 |
| The intimate relationship between gut microbiota and cancer immunotherapy A Elkrief, L Derosa, L Zitvogel, G Kroemer, B Routy Gut microbes 10 (3), 424-428, 2019 | 136 | 2019 |
| High mortality among hospital-acquired COVID-19 infection in patients with cancer: a multicentre observational cohort study A Elkrief, A Desilets, N Papneja, L Cvetkovic, C Groleau, YA Lakehal, ... European Journal of Cancer 139, 181-187, 2020 | 89 | 2020 |
| Predicted long‐term impact of COVID‐19 pandemic‐related care delays on cancer mortality in Canada T Malagón, JHE Yong, P Tope, WH Miller Jr, EL Franco, ... International journal of cancer 150 (8), 1244-1254, 2022 | 87 | 2022 |
| Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real … A Desilets, F Blanc-Durand, S Lau, T Hakozaki, R Kitadai, J Malo, ... European Journal of Cancer 142, 83-91, 2021 | 65 | 2021 |
| COVID-19 and Cancer Consortium NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study …, 2020 | 65 | 2020 |
| The role of the gut microbiome on radiation therapy efficacy and gastrointestinal complications: A systematic review M Tonneau, A Elkrief, D Pasquier, TP Del Socorro, M Chamaillard, ... Radiotherapy and Oncology 156, 1-9, 2021 | 62 | 2021 |
| Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition A Rogiers, IP Da Silva, C Tentori, CA Tondini, JM Grimes, MH Trager, ... Journal for ImmunoTherapy of Cancer 9 (1), 2021 | 62 | 2021 |
| Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC JV Alessi, A Elkrief, B Ricciuti, X Wang, A Cortellini, VR Vaz, G Lamberti, ... Journal of Thoracic Oncology 18 (6), 731-743, 2023 | 61 | 2023 |
| Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer B Ricciuti, JV Alessi, A Elkrief, X Wang, A Cortellini, YY Li, VR Vaz, ... Annals of Oncology 33 (10), 1029-1040, 2022 | 59 | 2022 |
| Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: a retrospective multicentric cohort study X Deschênes-Simard, C Richard, L Galland, F Blais, A Desilets, J Malo, ... Thrombosis Research 205, 29-39, 2021 | 51 | 2021 |